Abstract
Background: Poor medication adherence is a major public health concern. Patients living with a serious mental illness (SMI) commonly present with non-adherence to their medication regimen, which can lead to relapse and hospitalizations. The high rates of antipsychotic non-adherence continue to persist despite several interventions and medication advances. This review evaluates the possible role of the ingestible sensor technology for medication adherence in different conditions, with a focus on use in the SMI schizophrenia. Methods: Literature searches were conducted in July 2019 in the PubMed database. Results: In small studies of ingestible sensor use, the average adherence ranged from 73.9% to 88.6% for SMI and ≥ 80% for cardiac and transplant (99.4%) patients. In SMI studies, patients were clinically stable, and the majority had a clinical global impression severity of “mild disease”. Patients generally experienced relatively minor dermatological adverse effects related to wearable sensor use. Conclusions: A medication with an ingestible sensor may help provide real-time objective medication-taking adherence information for clinicians. However, further studies are needed to understand the impact of use on adherence and improvement on treatment outcomes with the ingestible sensor technology.
Highlights
Lack of adherence to medications is a significant public health issue
The Proteus digital medicine offering (DMO) can capture medication ingestions and other health information, which are later viewable by providers and patients [22]
An ingestible sensor may help address a gap in care by providing real-time objective medication-taking adherence information to clinicians
Summary
Lack of adherence to medications is a significant public health issue. According to the WorldHealth Organization (WHO), “adherence to medication can be defined as the degree to which use of medication by the patient corresponds with the prescribed regimen” [1]. Lack of adherence to medications is a significant public health issue. Relapse and hospitalization are major consequences of non-adherence in individuals with schizophrenia [4]. Poor medication adherence is a major public health concern. Patients living with a serious mental illness (SMI) commonly present with non-adherence to their medication regimen, which can lead to relapse and hospitalizations. This review evaluates the possible role of the ingestible sensor technology for medication adherence in different conditions, with a focus on use in the SMI schizophrenia. Results: In small studies of ingestible sensor use, the average adherence ranged from 73.9% to 88.6% for SMI and ≥ 80% for cardiac and transplant (99.4%) patients. Further studies are needed to understand the impact of use on adherence and improvement on treatment outcomes with the ingestible sensor technology
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
